The company's therapeutic, MIF-2, targets a novel biological pathway to protect tissue from ischemia-induced death, facilitating tissue regeneration for post-heart attack, cardiac surgery, or acute kidney injury and curing tissue death following traumatic injury to vital organs. MIFCOR's innovative therapy enhances the body's natural defense mechanisms to reduce ischemic injury to the heart and kidney. With no available drug that reduces tissue death during heart attack, MIFCOR's biologic therapeutic addresses a great need. The company has taken concrete steps towards commercialization, including executing an exclusive option on an IP portfolio, building a business plan, assembling a team of world-class advisors, and attracting potential investors.